Abstract
The development of pharmacologic agents for the prevention of breast cancer is a significant milestone in medical and laboratory research. Despite these advances, the endorsement of preventive options has become challenging and complex, as physicians are expected to counsel and tailor their recommendations using a personalized approach taking into account medical comorbidities, degree of risk and patient preferences. This article provides a comprehensive overview of the major breast cancer prevention trials, review of the pharmacologic options available for breast cancer prevention, and strategies for integrating chemoprevention of breast cancer in high-risk women into clinical practice.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 635-646 |
| Number of pages | 12 |
| Journal | Women's Health |
| Volume | 8 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2012 |
Keywords
- Gail Model
- aromatase inhibitor
- breast cancer prevention
- breast cancer risk
- chemoprevention
- high-risk women
- raloxifene
- tamoxifen
ASJC Scopus subject areas
- General Medicine